Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Conditions: Digestive System Neuroendocrine Neoplasm; Lung Neuroendocrine Neoplasm; Malignant Solid Neoplasm; Pancreatic Neuroendocrine Neoplasm Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Incomplete Freund ' ' s Adjuvant; Procedure: Magnetic Resonance Imaging; Biological: Sargramostim; Biological: SVN53-67/M57-KLH Peptide Vaccine; Drug: Temozolomide Sponsors: Roswell Park Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials